Bavarian Nordic A/S clarifies details on the Health Emergency Preparedness and Response Authority (HERA) framework agreement and the Public Preparedness business. An initial order for 750,000 doses of MVA-BN smallpox/mpox vaccine will be delivered in 2026 as part of a joint procurement contract by the European Commission through HERA. This order follows a previous contract option from BARDA announced in May. The company expects additional orders for MVA-BN, with the BARDA and HERA orders marking a promising start to a preparedness business worth DKK 1.5-2 billion for 2026. The HERA agreement does not impact the 2025 guidance. Bavarian Nordic is a global vaccine company focused on innovative vaccines for public health preparedness. For more information, visit www.bavarian-nordic.com. Contact investors: Europe – Disa Tuominen, IR Manager, [email protected]; US – Graham Morrell, Gilmartin Group, [email protected], Tel: +1 781 686 9600. Contact media: Nicole Seroff, Vice President Corporate Communications, [email protected], Tel: +45 53 88 06 03.

Read more at GlobeNewswire: Bavarian Nordic Provides Clarification on the HERA